M Hachiya, T Sakurai, Y Nagata, A Hidaka, Y Akita, H Miyashita, Y Maruyama, R Miyazaki, M Noguchi, R Sawada, J Mitobe, M Mitsunaga, T Yamasaki, T Kato, M Saruta, Journal of Crohn’s and Colitis, Volume 12, Issue supplement_1, February 2018,

Approximately 30% of all cases and 50% of severe cases that had received biologics were not able to avoid surgery. In severe cases, it is important to evaluate early treatment efficacy and prognostic factors because the median time of administration of biologics was only 9 weeks. However, no independent prognostic factor was found in this study.

https://academic.oup.com/ecco-jcc/article/12/supplement_1/S173/4808214

Yong Eun Park ¹, Jae Hee Cheon ^1 2 , Korean J Intern Med. 2018 Jan;33(1):1-19.

Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.

https://pubmed.ncbi.nlm.nih.gov/29207867/